CAR T therapy beyond cancer: the evolution of a living drug
Engineering a patient's own T cells to selectively target and eliminate tumour cells has cured
patients with untreatable haematologic cancers. These results have energized the field to …
patients with untreatable haematologic cancers. These results have energized the field to …
Advances in immunotherapy for triple-negative breast cancer
Y Liu, Y Hu, J Xue, J Li, J Yi, J Bu, Z Zhang, P Qiu… - Molecular cancer, 2023 - Springer
Background Immunotherapy has recently emerged as a treatment strategy which stimulates
the human immune system to kill tumor cells. Tumor immunotherapy is based on immune …
the human immune system to kill tumor cells. Tumor immunotherapy is based on immune …
Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer
U Amit, U Uslu, II Verginadis, MM Kim… - Proceedings of the …, 2024 - pnas.org
Pancreatic ductal adenocarcinoma (PDAC) represents a challenge in oncology, with limited
treatment options for advanced-stage patients. Chimeric antigen receptor T cell (CAR T) …
treatment options for advanced-stage patients. Chimeric antigen receptor T cell (CAR T) …
Advanced multiparametric image spectroscopy and super-resolution microscopy reveal a minimal model of CD95 signal initiation
N Bartels, NTM van der Voort, O Opanasyuk… - Science …, 2024 - science.org
Unraveling the concentration-dependent spatiotemporal organization of receptors in the
plasma membrane is crucial to understand cell signal initiation. A paradigm of this process is …
plasma membrane is crucial to understand cell signal initiation. A paradigm of this process is …
The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion
U Uslu, L Sun, S Castelli, AV Finck… - Nature …, 2024 - nature.com
As a strategy to improve the therapeutic success of chimeric antigen receptor T cells (CART)
directed against solid tumors, we here test the combinatorial use of CART and IMSA101, a …
directed against solid tumors, we here test the combinatorial use of CART and IMSA101, a …
Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment
Summary The Chimeric Antigen Receptor (CAR) T cell therapy has emerged as a ground-
breaking immunotherapeutic approach in cancer treatment. To overcome the complexity and …
breaking immunotherapeutic approach in cancer treatment. To overcome the complexity and …
Claudin18. 2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
C Qi, C Liu, J Gong, D Liu, X Wang, P Zhang, Y Qin… - Nature Medicine, 2024 - nature.com
Abstract Claudin18. 2 (CLDN18. 2) is highly expressed with the development of various
malignant tumors, especially gastrointestinal cancers, and is emerging as a new target for …
malignant tumors, especially gastrointestinal cancers, and is emerging as a new target for …
Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy: A Review
Importance Chimeric antigen receptor (CAR) T-cell therapy has redefined the therapeutic
landscape of several hematologic malignant tumors. Despite its clinical efficacy, many …
landscape of several hematologic malignant tumors. Despite its clinical efficacy, many …
Beyond the blood: expanding CAR T cell therapy to solid tumors
U Uslu, CH June - Nature Biotechnology, 2024 - nature.com
Chimeric antigen receptor (CAR) T cell therapy stands as a transformative advancement in
immunotherapy, triumphing against hematological malignancies and, increasingly …
immunotherapy, triumphing against hematological malignancies and, increasingly …
Biomaterials to enhance adoptive cell therapy
N Eckman, A Nejatfard, R Cavet… - Nature Reviews …, 2024 - nature.com
Adoptive cell therapy (ACT) harnesses the capabilities of immune cells to fight complex
diseases such as cancer. Treatment with adoptive transfer of engineered cells has led to …
diseases such as cancer. Treatment with adoptive transfer of engineered cells has led to …